Ensaio de fase II de braço único de capecitabina em dose baixa em pacientes com câncer de mama avançado
This is a phase II study aiming at evaluating capecitabine prospectively at a dose of 1000 mg once daily in patients with advanced breast cancer who are ≥60 years of age, or frail at any age, with a greater risk of complications and poorer outcomes with other treatments.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
The study is a phase II, single arm study in which all patients will receive the study drug. Participants will include older/frail patients with metastatic breast cancer.
All patients will be treated with capecitabine 1000 mg daily. There will be a total of 40 participants with measurable disease on this trial.
The study will encompass participants with locally advanced unresectable/metastatic breast cancer with measurable disease, who progressed on at least 1 prior therapy in the metastatic setting. Breast cancer subtypes include HR+ HER2 negative, or TNBC, age ≥ 60 years old, or frail patients at a younger age. ECOG PS 0- 2.
The study will discontinue if progressive disease or unacceptable toxicity is noted.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Contato de estudo
- Nome: Margaret Thomas, MPH
- Número de telefone: 205-895-1802
- E-mail: margaretathomas@uabmc.edu
Estude backup de contato
- Nome: Katia Khouri, MD
- Número de telefone: 216-556-3035
- E-mail: katia.khoury@gunet.georgetown.edu
Locais de estudo
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35294
- Recrutamento
- University of Alabama at Birmingham
-
Subinvestigador:
- Katia Khoury, MD
-
Subinvestigador:
- Gabrielle Rocque, MD
-
Contato:
- Humaria Sarfraz, MD
- Número de telefone: 205-975-2891
- E-mail: humairasarfraz@uabmc.edu
-
Investigador principal:
- Humaria Sarfraz, MD
-
Subinvestigador:
- Mauricio Escobar, MD
-
Subinvestigador:
- Nustrat Jahan, MD
-
Subinvestigador:
- Erica Stringer-Reasor, MD
-
Subinvestigador:
- Allison Richard, MD
-
Subinvestigador:
- Lisle Nabell, MD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Histologically or cytologically confirmed breast cancer with HER2 negative status. A copy of the pathology report is required at the time of enrollment.
- HER2 negativity will be determined by in situ hybridization (ISH) non- amplified and IHC 0 or 1+ or 2+.
- Patients with HR (hormone receptor) positive and triple negative breast cancer (TNBC) will be eligible for enrollment.
-
Metastatic or locally advanced breast cancer, with at least one measurable lesion according to RECIST (v1.1).
-
ECOG performance status of 0-2.
-
Patients must have progressed on at least 1 prior line of therapy in the metastatic setting (hormonal therapy or chemotherapy)
-
Adequate organ function as evidenced by:
-
ANC >1.5 x 10⁹/L (1500/µL) or > 1.3 x 10⁹/L (1300/µL) for patients with history of benign ethnic neutropenia.
-
Platelet count ≥100,000/µL (without transfusion within 2 weeks prior to initiation of study treatment (Cycle 1, day 1)).
-
Hemoglobin ≥9.0 g/dl. Patients may be transfused or receive erythropoietic treatment to meet this criterion.
-
AST, ALT, and alkaline phosphatase ≤2.5 x upper limit of normal (ULN) with following exceptions: I. Patients with documented liver metastasis: AST and ALT ≤5 x ULN II. Patients with documented liver or bone metastasis: alkaline phosphatase ≤5 x ULN
-
Serum bilirubin ≤1.5 x ULN
• Patients with known Gilbert disease who have serum bilirubin level ≤3 x ULN may be enrolled.
-
INR and aPTT ≤1.5 x ULN
• This applies only to the patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose.
-
Creatinine clearance > 30 mL/min (measured using Cockcroft-Gault equation or estimated glomerular filtration rate from the Modification of Diet in Renal Disease Study)
-
-
Patients must be able to provide signed informed consent.
-
Female patients of any ethnic group. Female patients must be surgically sterile, postmenopausal (no menses for at least one year), or using medically approved method of contraception (excluding rhythm, withdraw or abstinence). Men must agree to use a medically approved method of contraception (excluding rhythm, withdraw or abstinence).
-
Patients ≥60 years old and/or frail patients at any age, defined by the investigator as an individual at greater risk of complications and poorer outcomes with systemic therapy, secondary to a lower physiologic reserve and higher comorbidities and functional deficits.
-
Complete initial work-up within 2 weeks prior to start of treatment (Cycle 1 Day 1).
-
Patients known to be HIV positive are eligible if they meet the inclusion criteria.
Exclusion Criteria:
- Any history of treatment with Capecitabine in metastatic setting.
- Patients who only have non-measurable disease.
- Patients with severe hepatic (bilirubin > 3 times upper limit of normal) or renal failure (CrCl < 30 calculated using Cockcroft-Gault formula).
- Patients who are unable to swallow pills
- Patients with HER2 positive breast cancer
- Major surgical procedure within 3 weeks prior to study entry.
- Spinal cord compression not definitively treated with surgery and/or radiation, or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for >2 weeks prior to initiation of study treatment (Cycle 1, Day 1)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Low dose capecitabine (Xeloda)
1000 mg capecitabine daily by mouth. |
Will be given once per day by mouth
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Objective response rate (RR) evaluation
Prazo: Baseline up to 12 weeks
|
Evaluate response rate (RR) as defined per Response Evaluation Criteria in Solid Tumors (RECIST) criteria (v 1.1). Response and progression of disease will be evaluated in this study using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee; version 1.1. Patients will be evaluated for response every 12 weeks per RECIST Criteria. |
Baseline up to 12 weeks
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Progression-free survival (PFS)
Prazo: Up to 36 months
|
Initiation of treatment to the occurrence of disease progression or death. The RECIST v. 1.1 criteria will be used to evaluate progression-free survival as well as CT and PET scans. Baseline to the date of first documented progression to date of death from any cause, whichever comes first, assessed up to 36 months. |
Up to 36 months
|
|
Overall survival (OS)
Prazo: Baseline up to 36 months
|
The time which begins at diagnosis (or at the start of treatment) and up to the time of death. |
Baseline up to 36 months
|
|
Number of adverse events
Prazo: Baseline up to 36 months
|
Incidence of Treatment-Emergent Adverse Events will be graded using the Common Terminology Criteria for Adverse Events (CTCAE) v. 5.0. Safety, tolerability, satisfaction, and quality of life assessed using the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30) questionnaire, as well as the PRO-CTCAE (Patient reported outcomes - Common Terminology Criteria for Adverse Events) questionnaire. |
Baseline up to 36 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Humaria Sarfraz, MD, The University of Alabama at Birmingham
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Neoplasias por local
- Neoplasias
- Doenças de pele
- Doenças da mama
- Doenças da Pele e do Tecido Conjuntivo
- Neoplasias da Mama
- Compostos heterocíclicos, 1 anel
- Compostos heterocíclicos
- Ácidos nucleicos, nucleotídeos e nucleosídeos
- Desoxicitidina
- Citidina
- Nucleosídeos de pirimidina
- Pirimidinas
- Nucleosídeos
- Uracil
- Pirimidinonas
- Desoxirribonucleosídeos
- Fluorouracil
- Capecitabina
Outros números de identificação do estudo
- IRB-300012026 (UAB23115)
- Breast Cancer Foundation (Outro identificador: Breast Cancer Foundation)
- Robert Award (Outro identificador: UAB Cancer Center)
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .